GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Phreesia Inc (NYSE:PHR) » Definitions » Cash Conversion Cycle

Phreesia (Phreesia) Cash Conversion Cycle : 27.14 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Phreesia Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Phreesia's Days Sales Outstanding for the three months ended in Jan. 2024 was 54.97.
Phreesia's Days Inventory for the three months ended in Jan. 2024 was 0.
Phreesia's Days Payable for the three months ended in Jan. 2024 was 27.83.
Therefore, Phreesia's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2024 was 27.14.


Phreesia Cash Conversion Cycle Historical Data

The historical data trend for Phreesia's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phreesia Cash Conversion Cycle Chart

Phreesia Annual Data
Trend Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Cash Conversion Cycle
Get a 7-Day Free Trial 16.01 25.99 37.90 33.24 30.14

Phreesia Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.73 27.95 28.71 21.93 27.14

Competitive Comparison of Phreesia's Cash Conversion Cycle

For the Health Information Services subindustry, Phreesia's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phreesia's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Phreesia's Cash Conversion Cycle falls into.



Phreesia Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Phreesia's Cash Conversion Cycle for the fiscal year that ended in Jan. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=58.57+0-28.43
=30.14

Phreesia's Cash Conversion Cycle for the quarter that ended in Jan. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=54.97+0-27.83
=27.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phreesia  (NYSE:PHR) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Phreesia Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Phreesia's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Phreesia (Phreesia) Business Description

Traded in Other Exchanges
Address
1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, USA, 19803
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
Executives
Balaji Gandhi officer: Chief Financial Officer PHREESIA, INC., 1521 CONCORD PIKE, SUITE 301, PMB 221, WILMINGTON DE 19803
Allison C Hoffman officer: General Counsel & Secretary 315 EAST 68TH STREET, NEW YORK NY 10065
Amy Beth Vanduyn officer: SVP, Human Resources C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Chaim Indig director, officer: Chief Executive Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Michael J. Davidoff officer: See Remarks C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
David Linetsky officer: SVP, Life Sciences C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Evan Roberts officer: Chief Operating Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Janet Gunzburg officer: Principal Accounting Officer BANKRATE, INC., 477 MADISON AVENUE, SUITE 430, NEW YORK NY 10022
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
Gillian Munson director C/O XO GROUP INC., 195 BROADWAY, 25TH FLOOR, NEW YORK NY 10007
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Randy Rasmussen officer: Chief Financial Officer PHREESIA, INC., 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC 27601
Ramin Sayar director 305 MAIN STREET, REDWOOD CITY CA 94063
Michael Weintraub director C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Edward L Cahill 10 percent owner C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 200, WALTHAM MA 02453